布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病的临床疗效和安全性

摘要

Objective To study the clinical effect and safety of budesonide/formoterol inhalant combined with tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD). Methods A total of 90 COPD patients were randomly divided into observation group, control A group, and control B group, with 30 cases in each group. The control A group received tiotropium bromide for treatment, and control B group received budesonide/formoterol for treatment, while the observation group was treated by budesonide/formoterol combined with tiotropium bromide. Curative effects of the three groups were observed. Results The observation group had remarkably better forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and FEV1 predicted percentage than control A and B groups. The difference had statistical significance (P<0.05). The observation group had better clinical indexes than that before treatment and control A and B groups, and the difference had statistical significance (P<0.05). No obvious adverse reactions were found in all three groups. Conclusion Budesonide/formoterol combined with tiotropium bromide inhalant can effectively control clinical symptoms in treating COPD. It can improve patients’pulmonary function and life quality with high safety.%目的：研究布地奈德福莫特罗粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的临床疗效和安全性。方法90例慢性阻塞性肺疾病患者，随机分为观察组和对照A、B组，每组30例。对照A组接受噻托溴铵治疗，对照B组接受布地奈德/福莫特罗治疗，观察组采用噻托溴铵联合布地奈德/福莫特罗治疗。观察三组治疗效果。结果观察组的一秒用力呼气容积(FEV1)、最大呼气流速(PEF)和FEV1预计百分比，明显优于对照A、B组，差异均具有统计学意义(P<0.05)；观察组临床指标较治疗前和对照A、B组更优(P<0.05)。三组患者未见明显不良反应。结论布地奈德/福莫特罗联合噻托溴铵吸入治疗慢性阻塞性肺疾病有利于控制临床症状，改善患者肺功能与生活质量，安全性高。